Table 1.
Description of the study population: 56 male individuals with a history of coronary artery disease.
| Clinical Characteristics | Mean (± SD) | |
|---|---|---|
| Age [years] | 66 (± 6) | |
| Body mass index (BMI) [kg/m2] | 28 (± 4) | |
| Total number N (%) | ||
| History of myocardial infarction | 43 (77) | |
| Revascularization (CABG/PTCAa) | 48 (86) | |
| Type 2 diabetes mellitus | 12 (21) | |
| Hypertensionb | 39 (70) | |
| NYHA≥ II | 17 (30) | |
| COPD | 5 (9) | |
| Occupational status: | - Work part time or full time | 4 (7) |
| - Retired | 49 (88) | |
| - Unable to work or unemployed | 3 (5) | |
| - Exposed to toxic gases, dust or fumes at work |
1 (2) | |
| Smoking: | - Never-smoker | 15 (27) |
| - Ex-smoker | 41 (73) | |
| Medication use: | - Beta-adrenergic receptor blockers | 43 (77) |
| - Anti-arrhythmic therapy | 2 (4) | |
| - ACE-inhibitors | 30 (54) | |
| - Calcium-blockers | 17 (30) | |
| - Nitrates | 24 (43) | |
| - Acetylsalicylic acid (aspirin) | 46 (82) | |
| - Statins and Fibrates | 29 (52) | |
SD: standard deviation; CABG: coronary artery bypass graft surgery; PTCA: percutaneous transluminal coronary angioplasty; NYHA: New York Health Association functional classification; COPD: chronic obstructive pulmonary disease; ACE: angiotensin-converting enzyme.
aBoth procedures had to be performed more than three months prior to enrolment.
bInformation from self-administered baseline questionnaire.